<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736953</url>
  </required_header>
  <id_info>
    <org_study_id>Rapamycin</org_study_id>
    <nct_id>NCT04736953</nct_id>
  </id_info>
  <brief_title>Sirolimus Treatment Of Patients With SLE</brief_title>
  <acronym>STOPSLE</acronym>
  <official_title>Sirolimus Treatment of Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Double-blind, placebo-controlled, randomized treatment trial with two arms: one&#xD;
      SIROLIMUS arm with 92 patients and one placebo arm with 92 patients. The safety and&#xD;
      therapeutic efficacy of SIROLIMUS will be determined within a dosage range of 1 mg/day to 4&#xD;
      mg/day, which will be titrated to tolerance during an initial 3-month open label period,&#xD;
      relative to placebo in SLE patients over 12 months followed by a 1-month washout. The&#xD;
      proposed study design, known as an enriched enrollment randomized withdrawal (EERW), has&#xD;
      major advantages that (1) only people who tolerate SIROLIMUS are randomized, potentially&#xD;
      reducing the percentage of dropouts in the randomized phase and (2) it allows participants to&#xD;
      use an individualized dosage of study medication, which mimics clinical practice in terms of&#xD;
      how SIROLIMUS would be administered. Healthy subjects receive no drugs and serve as controls&#xD;
      for in vitro studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Benefit</measure>
    <time_frame>12 months</time_frame>
    <description>Positive Response on SLE Responder Index (SRI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus 1 to 2 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 to 2 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18;&#xD;
&#xD;
          2. Male or female;&#xD;
&#xD;
          3. ≥ 4 ACR SLE classification criteria;&#xD;
&#xD;
          4. Positive ANA at a titer of ≥ 1/80;&#xD;
&#xD;
          5. Stable immunosuppressants (MMF ≤ 3 g/day, azathioprine ≤ 100 mg/day; methotrexate ≤ 15&#xD;
             mg/day) and/or antimalarials (hydroxychloroquine ≤ 400 mg/day) for 30 days prior to&#xD;
             screening; stable oral corticosteroids for 2 weeks prior to screening; ≤ 20 mg/day&#xD;
             prednisone or equivalent; stable belimumab for 90 days prior to screening;&#xD;
&#xD;
          6. BILAG 2004 index (3) level A disease activity in ≥ 1 organ/system except renal or&#xD;
             central nervous system or (ii) BILAG 2004 index level B disease activity in ≥ 2&#xD;
             organs/systems if no level A disease activity is present and (iii) SLEDAI ≥ 6;&#xD;
&#xD;
          7. Enrollment is approved by adjudication committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute SLE flare threatening vital organs;&#xD;
&#xD;
          2. Pregnant or lactating;&#xD;
&#xD;
          3. Female subjects who are planning to become pregnant during the study or within 3&#xD;
             months after last dosing or male subjects who are considering fathering a child within&#xD;
             3 months after last dosing;&#xD;
&#xD;
          4. Abnormal laboratory test results: hemoglobin ≤ 8 g/L (8 g/dL), platelet count ≤ 70 x&#xD;
             109/L (70,000 cells/mm³), white blood cell count ≤ 2.0 x 109/L (2,000 cells/mm³),&#xD;
             neutrophils: ≤ 1.5 X 109/L, proteinuria &gt; 3 g/day measured by 24 hour collection or&#xD;
             spot urine protein to creatinine ratio of &gt;3;&#xD;
&#xD;
          5. Glomerular filtration rate (GFR) &lt; 50 mL/min/1.73 m², any other clinically significant&#xD;
             abnormal screening laboratory results as evaluated by the Investigator;&#xD;
&#xD;
          6. Moderately serious or serious comorbidities (e.g., diabetes mellitus, congestive heart&#xD;
             failure, chronic obstructive pulmonary disease, chronic renal insufficiency) that in&#xD;
             investigator's opinion confers high risk for adverse events;&#xD;
&#xD;
          7. Patients receiving cyclophosphamide within 3 months;&#xD;
&#xD;
          8. Active chronic infections (e.g., HIV, hepatitis B virus, hepatitis C virus,&#xD;
             mycobacteria); patients with oral steroid-dependent asthma;&#xD;
&#xD;
          9. Infections requiring intravenous antibiotics within a month or oral antibiotics within&#xD;
             two weeks of screening;&#xD;
&#xD;
         10. Patients taking (unwilling or unable to stop) NAC or other antioxidants within 1 month&#xD;
             of screening (which is considered sufficient time to revert GSH to pre-treatment&#xD;
             levels;&#xD;
&#xD;
         11. Patients receiving rituximab within 12 months or other biologic therapy within five&#xD;
             half lives;&#xD;
&#xD;
         12. Patients receiving mTOR inhibitors (rapamycin/sirolimus, everolimus);&#xD;
&#xD;
         13. Patients enrolled in other interventional trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Andras Perl, MD, Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

